Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABEO vs PTNQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: ABEO 4 – 1 PTNQ (1 Tie) Matrix Metrics: ABEO 7 – 3 PTNQ

As of Nov 16, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over Pacer Trendpilot 100 ETF (PTNQ) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABEO carries a Unified Composite Score of 44.9/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin), whereas PTNQ carries 54.5/100 (HOLD) at $79.80 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While PTNQ currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. ABEO 44.9/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. N/A operating margin) and revenue trajectory (+2745.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2); meanwhile PTNQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABEO vs PTNQ
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.60
+7.44% 1D
Market Cap $149.2M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
44.9 / 100 HOLD
Tech 60.0 Fund 52.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.5%), weak momentum, RSI 26
RSI-14: 26.2 · SMA20: $3.78 · SMA50: $4.63
PTNQ NASDAQ
Pacer Trendpilot 100 ETF
Institutional Equity
$79.80
-2.59% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.40β · 35% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 56.0 Fund 61.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.4%), weak momentum, RSI 38
RSI-14: 37.5 · SMA20: $83.50 · SMA50: $86.41

6-Pillar Scorecard Institutional Category Breakdown (ABEO 4 – 1 PTNQ)

Columns: Metric · ABEO · PTNQ
1. Valuation Multiples ABEO
Forward P/E 18.7x N/M
Trailing P/E 18.7x N/M
PEG Ratio N/M N/M
EV / Revenue 2.6x N/M
2. Growth & Scale ABEO
Revenue Growth (YoY) +2745.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $39M N/A
Market Cap $149.2M N/A
3. Profitability & Quality ABEO
Gross Margin -3.5% N/A
Operating Margin -186.1% N/A
Net Profit Margin -160.3% N/A
Return on Equity (ROE) -42.1% N/A
4. Balance Sheet & Cash Flow ABEO
Cash Generation (TTM) -$66M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $50M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PTNQ
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 165.8% (27th %ile) N/A (N/A)
Put/Call OI Skew 0.19x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABEO (7) vs PTNQ (3)
Institutional Metric ABEO PTNQ Criterion Row Edge
Market Capitalization
Scale
$149.2M N/A Larger Scale ABEO
Trailing P/E Ratio
Valuation
18.7x N/M Lower Multiple ABEO
Forward P/E Ratio
Valuation
18.7x N/M Lower Multiple ABEO
Revenue Growth (YoY)
Growth
+2745.0% N/A Higher Growth ABEO
Operating Margin (TTM)
Profitability
-186.1% N/A Higher Margin ABEO
Net Profit Margin
Profitability
-160.3% N/A Higher Margin ABEO
Return on Equity (ROE)
Capital Efficiency
-42.1% N/A Higher ROE ABEO
52-Week Range Position
Momentum
9% ($2–$8) 40% ($72–$92) Stronger Trend PTNQ
Beta / 30D Volatility
Risk Regime
0.60β · 149% Vol 1.40β · 35% Vol Lower Realized Risk PTNQ
Unified Institutional Score
Composite Signal
44.9 / 100 (HOLD) 54.5 / 100 (HOLD) Higher Composite PTNQ
Trailing 12M Revenue (USD)
Operating Scale
$39M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-3.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$66M ($50M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTNQ +34.5 pp
ABEO: -41.31% · PTNQ: -6.81%
3M Horizon PTNQ +50.04 pp
ABEO: -57.79% · PTNQ: -7.75%
6M Horizon PTNQ +45.45 pp
ABEO: -51.58% · PTNQ: -6.13%
1Y Horizon PTNQ +44.24 pp
ABEO: -42.6% · PTNQ: +1.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABEO vs PTNQ. Trailing 12-month operating profitability (ABEO -186.1% vs PTNQ N/A) and valuation multiples (ABEO 18.7x vs PTNQ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABEO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-3.5%
Op. Margin-186.1%
ROE / Fwd P/E-42.1% · 18.7x
PTNQ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABEO BREAKDOWN
67d in phase · OBV DISTRIBUTION
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTNQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTNQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $149.2M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTNQ Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABEO vs PTNQ Key Questions & Quantitative Answers

As of Nov 16, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over Pacer Trendpilot 100 ETF (PTNQ) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABEO carries a Unified Composite Score of 44.9/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin), whereas PTNQ carries 54.5/100 (HOLD) at $79.80 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While PTNQ currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. ABEO 44.9/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. N/A operating margin) and revenue trajectory (+2745.0% vs. N/A YoY). Technical & Structure Timing Caution: ABEO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2); meanwhile PTNQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: ABEO posts +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin), compared with PTNQ at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABEO generates $39M in USD-normalized revenue versus N/A for PTNQ. In operating R&D and SG&A reinvestment, ABEO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PTNQ.

ABEO screens cheaper on headline valuation multiples. ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin), whereas PTNQ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABEO (-42.1% ROE) versus PTNQ (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk). By comparison, PTNQ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.